Malaria vaccine offers new mode of protection against disease

November 29, 2013
Malaria vaccine offers new mode of protection against disease
Malaria parasites carried by mosquitoes kill more than 660,000 people each year

(Medical Xpress)—A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial to test whether it can protect people against the mosquito-borne disease.

The trial was carried out in Oxford by researchers led by Professor Adrian Hill of the Jenner Institute at Oxford University, along with colleagues from the biotechnology company Okairos.

Some of the adult volunteers were completely protected against malaria in this initial study of the vaccine's efficacy.

It's the first time that a vaccine has been shown to have a protective effect through a sufficiently high involving called CD8 T cells.

It is CD8 immune cells that are seen to mount a protective response against malaria in similar studies in mice.

Every existing vaccine in use – bar one – generates antibodies. But there are two arms to the body's immune system for fighting infection: antibodies and T cells. And this vaccine aims to stimulate an immune response involving T cells.

CD8 T cells are important because they are the primary killer cells in the immune system. They can attack nearly all types of – in this case liver cells infected with the . But this first demonstration of a large CD8 response from a vaccine could be relevant for tackling other diseases too.

'The vaccine was found to work by inducing CD8+ T cells that target the malaria parasite in the liver,' explains Professor Hill.

'For years a wide range of technologies have been assessed trying to induce protection through the cellular arm of the with CD8+ T cells. But this is the first time that this has been achieved for any vaccine type against any disease.'

The Phase IIa trial in Oxford involved 36 people in total, of which 14 healthy adults received two different virus-based vaccines with the same malaria antigen eight weeks apart.

Of those 14, three people were protected from the bites of malaria-infected mosquitoes. A further five had delayed onset of malaria, demonstrating that over 90% of the malaria parasites had been killed by the vaccine-induced immune response.

Importantly, the size of the CD8 T cell response in these volunteers correlated with the degree of protection from malaria, suggesting that a sufficiently high cellular immune response is protective.

Ten further volunteers received only one of the vaccines and there were 12 controls. None of these people saw any protection against malaria from mosquito bites on the arm. All volunteers were closely monitored for malaria symptoms throughout, and those getting the disease were treated rapidly with drugs.

The trial results are published in the journal Nature Communications. The study was funded by the Medical Research Council with support from the National Institute for Health Research and the Wellcome Trust.

The results of larger Phase IIb trials of the efficacy of the vaccine in Africa are expected in 2014. They will determine more about the efficacy of this where it is needed most.

If results continue to be positive, Professor Hill thinks that the best protection against malaria may come from combining the Oxford-developed vaccine with another that targets the sporozoite stage of the malaria parasite's life cycle. One such vaccine developed by GSK is in late-stage clinical trials.

The GSK vaccine called RTS,S works by stimulating antibodies against the parasites before they enter the liver. Those that reach the liver would be mopped up by T cells stimulated by the Oxford .

Professor Hill and colleagues are currently carrying out a study in the UK to test how the GSK and Oxford vaccines might work together.

Malaria kills more than 660,000 people each year, most of whom are children in Africa.

Explore further: Weakened malaria parasites form basis of new vaccine strategy

More information: www.nature.com/ncomms/2013/131 … full/ncomms3836.html

Related Stories

Weakened malaria parasites form basis of new vaccine strategy

September 8, 2011
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy, according to results of follow-up animal studies performed after the conclusion of a recent clinical ...

Mosquito bites deliver potential new malaria vaccine

September 11, 2013
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. ...

Australian researchers close in on malaria vaccine

July 2, 2013
Australian researchers said Tuesday they were closing in on a potential vaccine against malaria, with a study showing their treatment had protected mice against several strains of the disease.

Cross-species malaria immunity induced by chemically attenuated parasites

July 1, 2013
Malaria, a mosquito-born infectious disease, kills over 600,000 people every year. Research has focused on the development of a vaccine to prevent the disease; however, many malaria vaccines targeting parasite antigens have ...

Investigational malaria vaccine found safe and protective

August 8, 2013
An investigational malaria vaccine has been found to be safe, to generate an immune system response, and to offer protection against malaria infection in healthy adults, according to the results of an early-stage clinical ...

Recommended for you

Study finds harmful protein on acid triggers a life-threatening disease

July 27, 2017
Using an array of modern biochemical and structural biology techniques, researchers from Boston University School of Medicine (BUSM) have begun to unravel the mystery of how acidity influences a small protein called serum ...

CRISPR sheds light on rare pediatric bone marrow failure syndrome

July 27, 2017
Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells.

Post-stroke patients reach terra firma with new exosuit technology

July 26, 2017
Upright walking on two legs is a defining trait in humans, enabling them to move very efficiently throughout their environment. This can all change in the blink of an eye when a stroke occurs. In about 80% of patients post-stroke, ...

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

New vaccine production could improve flu shot accuracy

July 24, 2017
A new way of producing the seasonal flu vaccine could speed up the process and provide better protection against infection.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.